Hormone replacement therapy and the association with coronary heart disease and overall mortality: Clinical application of the timing hypothesis

Journal of Steroid Biochemistry and Molecular Biology

Volumn 142, Issue , 2014, Pages 68-75

  Hodis, Howard N ^a   Mack, Wendy J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Clinical trials; Coronary heart disease; Estrogen; Hormone therapy; Menopause; Mortality; Observational studies; Stroke; Timing hypothesis; Women

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; GESTAGEN; ISOFLAVONE; PLACEBO; RALOXIFENE; THREO 3,4 DIHYDROXYPHENYLSERINE;

CANCER PREVENTION; CEREBROVASCULAR ACCIDENT; CLIMACTERIUM; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HEALTH PROGRAM; HEART FAILURE; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LIFE EXTENSION; META ANALYSIS (TOPIC); MORTALITY; NONHUMAN; OBSERVATIONAL STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANIMALIA;

CLINICAL TRIALS; CORONARY HEART DISEASE; ESTROGEN; HORMONE THERAPY; MENOPAUSE; MORTALITY; OBSERVATIONAL STUDIES; STROKE; TIMING HYPOTHESIS; WOMEN;

AGED; ANIMALS; ATHEROSCLEROSIS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; LIGANDS; MENOPAUSE; MIDDLE AGED; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; RISK; STROKE; TIME FACTORS;

EID: 84899922469     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2013.06.011     Document Type: Article

References (47)

1. F. Grodstein, and M. Stampfer The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women Progress in Cardiovascular Diseases 38 1995 199 210
2. F. Grodstein, and M. Stampfer Estrogen for women at varying risk of coronary disease Maturitas 30 1998 19 26
3. S.G. Thompson, T.W. Meade, and G. Greenberg The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women Journal of Epidemiology & Community Health 43 1989 173 178
4. M. Falkeborn, I. Persson, and H.O. Adami The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement An International Journal of Obstetrics & Gynaecology 99 1992 821 828
5. B.M. Psaty, S.R. Heckbert, D. Atkins, R.N. Lemaitre, T.D. Koepsell, P.W. Wahl, D.S. Siscovick, and E.H. Wagneret The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women Archives of Internal Medicine 154 1994 1333 1339
6. F. Grodstein, M.J. Stampfer, J.E. Manson, G.A. Colditz, W.C. Willett, B. Rosner, F.E. Speizer, and C.H. Hennekens Postmenopausal estrogen and progestin use and the risk of cardiovascular disease The New England Journal of Medicine 335 1996 453 461
7. R.L. Prentice, R. Langer, M.L. Stefanick, B.V. Howard, M.L. Pettinger, G.L. Anderson, D. Barad, J.D. Curb, J. Kotchen, L. Kuller, M. Limacher, and J. Wactawski-Wende Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial American Journal of Epidemiology 162 2005 404 414
8. R.L. Prentice, R. Langer, M.L. Stefanick, B.V. Howard, M. Pettinger, G.L. Anderson, D. Barad, J.D. Curb, J. Kotchen, L. Kuller, M. Limacher, and J. Wactawski-Wende Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone therapy and cardiovascular disease American Journal of Epidemiology 163 2006 589 599
9. B.D. Henderson, A. Paganini-Hill, and R.K. Ross Decreased mortality in users of estrogen replacement therapy Archives of Internal Medicine 151 1991 75 78
10. F. Grodstein, J.E. Manson, G.A. Colditz, W.C. Willett, F.E. Speizer, and M.J. Stampfer A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease Annals of Internal Medicine 133 2000 933 941
11. H.N. Hodis, P. Collins, W.J. Mack, and L. Schierbeck The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective Climacteric 15 2012 217 228
12. S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, and E. Vittinghoff Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women JAMA 280 1998 605 613
13. D.M. Herrington, D.M. Reboussin, K.B. Brosnihan, P.C. Sharp, S.A. Shumaker, T.E. Snyder, C.D. Furberg, G.J. Kowalchuk, T.D. Stuckey, W.J. Rogers, D.H. Givens, and D. Waters Effects of estrogen replacement on the progression of coronary artery atherosclerosis The New England Journal of Medicine 343 2000 522 529
14. H.N. Hodis, W.J. Mack, R.A. Lobo, D. Shoupe, A. Sevanian, P.R. Mahrer, R.H. Selzer, C.R. Liu, C.H. Liu, and S.P. Azen Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial Annals of Internal Medicine 135 2001 939 953
15. H.N. Hodis, W.J. Mack, S.P. Azen, R.A. Lobo, D. Shoupe, P.R. Mahrer, D.P. Faxon, L. Cashin-Hemphill, M.E. Sanmarco, W.J. French, T.L. Shook, T.D. Gaarder, A.O. Mehra, R. Rabbani, A. Sevanian, A.B. Shil, M. Torres, K.H. Vogelbach, and R.H. Selzer Hormone therapy and the progression of coronary artery atherosclerosis in postmenopausal women The New England Journal of Medicine 349 2003 535 545
16. S.R. Salpeter, J.M.E. Walsh, E. Greyber, and E.E. Salpeter Coronary heart disease events associated with hormone therapy in younger and older women: a meta-analysis Journal of General Internal Medicine 21 2006 363 366
17. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy menopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 323
18. The Women's Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712
19. C. Rodriguez, E.E. Calle, A.V. Patel, L.M. Tatham, E.J. Jacobs, and M.J. Thun Effect of body mass on the association between estrogen replacement therapy and mortality among elderly US women American Journal of Epidemiology 153 2001 145 152
20. L.L. Schierbeck, L. Rejnmark, C.L. Tofteng, L. Stilgren, P. Eiken, L. Mosekilde, L. Kober, and J.E.B. Jensen Effect of hormone replacement treatment on cardiovascular events in recently postmenopausal women: randomized trial BMJ 345 2012 e6409
21. J. Hsia, R.D. Langer, J.E. Manson, L. Kuller, K.C. Johnson, S.L. Hendrix, M. Pettinger, S.R. Heckbert, N. Greep, S. Crawford, C.B. Eaton, J.B. Kostis, P. Caralis, and R. Prentice For the women's health initiative investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative Archives of Internal Medicine 166 2006 357 365
22. J.E. Rossouw, R.L. Prentice, J.E. Manson, L.L. Wu, D. Barad, V.M. Barnabei, M. Ko, A.Z. LaCroix, K.L. Margolis, and M.L. Stefanick Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause JAMA 297 2007 1465 1477
23. A.Z. LaCroix, R.T. Chlebowski, J.E. Manson, A.K. Aragaki, K.C. Johnson, L. Martin, K.L. Margolis, M.L. Stefanick, R. Brzyski, J.D. Curb, B.V. Howard, C.E. Lewis, and J. Wactawski-Wende For the WHI investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with hysterectomy: a randomized controlled trial JAMA 305 2011 1305 1314
24. J.E. Manson, M.A. Allison, J.E. Rossouw, J.J. Carr, R.D. Langer, J. Hsia, L.H. Kuller, B.B. Cochrane, J.R. Hunt, S.E. Ludlam, M.B. Pettinger, M. Gass, K.L. Margolis, L. Nathan, J.K. Ockene, R.L. Prentice, J. Robbins, and M.L. Stefanick For the WHI and WHI-CACS investigators. Estrogen therapy and coronary-artery calcification The New England Journal of Medicine 356 2007 2591 2602
25. S.R. Salpeter, J.M.E. Walsh, E. Greybe, T.M. Ormiston, and E.E. Salpeter Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis Journal of General Internal Medicine 19 2004 791 804
26. P. Collins, L. Mosca, M.J. Geiger, D. Grady, M. Kornitzer, M.G. Amewou-Atisso, M.B. Effron, S.A. Dowsett, E. Barrett-Connor, and N.K. Wenger Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the raloxifene use for the heart trial: results of subgroup analyses by age and other factors Circulation 119 2009 922 930
27. S.R. Cummings, K. Ensrud, P.D. Delmas, A.Z. LaCroix, S. Vukicevic, D.M. Reid, S. Goldstein, U. Sriram, A. Lee, J. Thompson, R.A. Armstrong, D.D. Thompson, T. Powles, J. Zanchetta, D. Kendler, P. Neven, and R. Eastell For the PEARL study investigators. Lasofoxifene in postmenopausal women with osteoporosis The New England Journal of Medicine 362 2010 686 696
28. H.N. Hodis, W.J. Mack, N. Kono, S.P. Azen, D. Shoupe, J. Hwang-Levine, D. Petitti, L. Whitfield, M. Yan, A.A. Franke, and R.H. Selzer For the WISH research group. Isoflavone soy protein supplementation and progression of subclinical atherosclerosis in healthy postmenopausal women: a randomized controlled trial Stroke 42 2011 3168 3175
29. M.R. Adams, T.C. Register, D.L. Golden, J.D. Wagner, and J.K. Williams Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis Arteriosclerosis, Thrombosis, and Vascular Biology 17 1997 217 221
30. T.B. Clarkson, M.S. Anthony, and C.P. Jerome Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys The Journal of Clinical Endocrinology and Metabolism 83 1988 721 726
31. T.B. Clarkson, M.S. Anthony, and T.M. Morgan Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens The Journal of Clinical Endocrinology and Metabolism 86 2001 41 47
32. J.K. Williams, M.S. Anthony, E.K. Honore, D.M. Herrington, T.M. Morgan, T.C. Register, and T.B. Clarkson Regression of atherosclerosis in female monkeys Arteriosclerosis, Thrombosis, and Vascular Biology 15 1995 827 836
33. M.E. Rosenfeld, K. Kauser, B. Martin-McNulty, P. Polinsky, S.M. Schwartz, and G.M. Rubanyi Estrogen inhibits the initiation of fatty streaks throughout the vasculature but does not inhibit intra-plaque hemorrhage and the progression of established lesions in apolipoprotein E deficient mice Atherosclerosis 164 2002 251 259
34. D.W. Losordo, M. Kearney, E.A. Kim, J. Jekanowski, and J.M. Isner Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women Circulation 89 1994 1501 1510
35. W.S. Post, P.J. Goldschmidt-Clemont, C.C. Wilhide, A.W. Heldman, M.S. Sussman, P. Ouyang, E.E. Milliken, and J.P.J. Issa Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system Cardiovascular Research 43 1999 985 991
36. A. Paganini-Hill Hormone replacement therapy and stroke: risk, protection or no effect Maturitus 38 2002 243 261
37. C.M. Viscoli, L.M. Brass, W.N. Kernan, P.M. Sarrel, S. Suissa, and R.I. Horwitz A clinical trial of estrogen replacement therapy after ischemic stroke The New England Journal of Medicine 345 2001 1243 1249
38. J.A. Simon, J. Hsia, J.A. Cauley, C. Richards, F. Harris, J. Fong, E. Barrett-Connor, and S.B. Hulley For the HERS Research Group. Postmenopausal hormone therapy and risk of stroke: the heart and estrogen-progestin replacement study (HERS) Circulation 103 2001 638 642
39. S. Wassertheil-Smoller, S.L. Hendrix, M. Limacher, G. Heiss, C. Kooperberg, A. Baird, T. Kotchen, J.D. Curb, H. Black, J.E. Rossouw, A. Aragaki, M. Safford, E. Stein, S. Laowattana, and W.J. Mysiw For the WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial JAMA 289 2003 2673 2684
40. L.H. Coker, P.E. Hogan, N.R. Bryan, L.H. Kuller, K.L. Margolis, K. Bettermann, R.B. Wallace, Z. Lao, R. Freeman, M.L. Stefanick, and S.A. Shumaker For the women's health initiative memory study. Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI study Neurology 72 2009 125 134
41. F. Grodstein, J.E. Manson, M.J. Stampfer, and K. Rexrode Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy Archives of Internal Medicine 168 2008 861 866
42. S.R. Salpeter, J. Cheng, L. Thabane, N.S. Buckley, and E.E. Salpeter Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women American Journal of Medicine 12 2009 1016 1022
43. S.R. Salpeter, N.S. Buckley, H. Liu, and E.E. Salpeter The cost-effectiveness of hormone therapy in younger and older postmenopausal women American Journal of Medicine 122 2009 42 52
44. D.J. Cohen, and M.R. Reynolds Interpreting the results of cost-effectiveness studies Journal of the American College of Cardiology 52 2008 2119 2126
45. H.N. Hodis, and W.J. Mack Postmenopausal hormone therapy in clinical perspective Menopause 14 2007 944 957
46. W.H. Utian A decade post WHI, menopausal hormone therapy comes full circle-need for independent commission Climacteric 15 2012 320 325
47. E. Davies, N.P. Mangongi, and C.L. Carter Is timing everything? A meeting report of the society for women's health research roundtable on menopausal hormone therapy Journal of Women's Health 22 2013 303 311